Vaccination programs are among the most effective public health interventions, significantly reducing child mortality and curbing the spread of infectious diseases. Vaccines work by stimulating the body’s immune system to build protection against pathogens, thereby lowering the risk of infection and severe illness. Immunization stands as a global health success story—according to the World Health Organization (WHO), vaccines prevent an estimated 3.5 to 5 million deaths annually from diseases such as diphtheria, tetanus, pertussis, influenza, and measles. Beyond individual protection, widespread vaccination fosters herd immunity, safeguarding vulnerable populations who cannot be vaccinated due to medical reasons. As a cornerstone of primary health care, immunization is not only a fundamental human right but also one of the most cost-effective health investments.

However, sustaining high vaccination coverage is critical to preventing disease resurgence and addressing emerging health threats. Despite these successes, recent funding cuts and rising vaccine skepticism threaten to undermine decades of progress. For instance, the United States has significantly reduced its aid programs, and the United Kingdom is considering similar funding reductions. These cuts could have far-reaching consequences, particularly for low-income regions that rely heavily on external support. Many global vaccination programs, including those supported by Gavi, the Vaccine Alliance—a public-private global health partnership aimed at increasing immunization access in low-income countries—are now facing significant funding shortfalls.

Developing countries, including India, rely heavily on financial support from organizations such as Gavi, the World Health Organization (WHO), and UNICEF for vaccine procurement and immunization campaigns. However, wealthy nations have reduced their contributions to global vaccination efforts. For example, the UK has cut aid to Gavi and the Global Polio Eradication Initiative (GPEI), which has directly impacted vaccine distribution in countries like India. Global economic challenges, including the post-COVID-19 slowdown, the Ukraine war, and rising inflation, have further strained foreign aid budgets. As a result, more funds are being diverted toward pandemic preparedness rather than routine immunization.

Low-income countries often face significant hurdles in vaccine procurement and distribution. India, in particular, has a dual role: protecting its own population while serving as a global vaccine supplier. India is a global leader in vaccine production, home to major manufacturers like the Serum Institute of India and Bharat Biotech. The country also runs one of the world’s largest immunization programs, Mission Indradhanush, which covers millions of children and pregnant women. However, funding constraints may hinder its expansion. Although India’s National Health Policy 2017 aims to increase public health spending to 2.5% of GDP by 2025, the 2024-25 budget allocated only about 2.1% of GDP to health, which is lower than many other countries.

India’s role as a global vaccine hub is undeniable, but the pace of new vaccine development is slow due to limited research and development (R&D) funding. Challenges such as funding shortages, vaccine hesitancy, and logistical issues could impede disease control efforts. Reduced global funding affects India’s ability to procure vaccines for diseases like polio and measles, especially in remote regions. Developing a new vaccine is a costly endeavor, ranging from 100 million to 500 million per vaccine, and India’s current funding for vaccine R&D is insufficient. This lack of funding translates to fewer vaccine outreach programs and delays in the rollout of new vaccines, such as those for HPV (to prevent cervical cancer), dengue, and tuberculosis (TB).

The Global Polio Eradication Initiative (GPEI) has also faced funding reductions, impacting India’s polio surveillance efforts. Additionally, India is grappling with rising cases of dengue and malaria, exacerbated by climate change. While Dengvaxia, a dengue vaccine, exists, its use is limited. Emerging threats, such as the mpox (monkeypox) outbreak, further underscore the need for robust vaccination campaigns. Although India has reported low mpox cases, ongoing surveillance is critical given the global spread of the disease.

The high cost of vaccines often results in lower coverage among low-income populations, increasing the risk of outbreaks for diseases such as measles, rubella, and diphtheria. This raises a critical question: Can India sustain its global vaccine supply amidst funding cuts and geopolitical challenges?

To address these challenges, several strategies can be considered. Private companies like the Serum Institute of India and Bharat Biotech may require government subsidies to scale up vaccine production. Long-term funding agreements with organizations such as WHO, Gavi, and UNICEF could ensure vaccine affordability. Additionally, tapping into corporate social responsibility (CSR) funding from Indian pharmaceutical giants could provide a sustainable financial model. For example, Gavi’s partnership with African nations to ensure polio vaccine affordability could serve as a blueprint for India’s efforts to combat measles and HPV.

Improving cold chain logistics is another critical area. India’s “eVIN” (Electronic Vaccine Intelligence Network) has already enhanced vaccine tracking and cold storage in rural areas, but further investments are needed. Introducing new vaccines into national programs, such as government-funded HPV and dengue vaccines, could help eliminate these diseases.

While India faces significant challenges in sustaining its vaccination programs, strategic investments, international collaborations, and innovative funding mechanisms can help mitigate the impact of global aid cuts. By addressing these issues, India can continue to protect its population and maintain its vital role as a global vaccine supplier.

Author’s biography

Akhter Rasool is a veterinarian and researcher.

The post Global Aid Cuts and India’s Vaccination Challenges appeared first on InnoHEALTH magazine.

At the InnoHEALTH Conference 2024, I had the privilege of speaking with Dr. Ravi Gaur, a renowned onco-pathologist with four decades of experience in diagnostics and precision medicine. Our discussion covered the impact of artificial intelligence (AI), healthcare accessibility, and the future of medical innovation in India.

AI in Healthcare: Friend or Foe?

With the rise of AI, many people worry that it might replace human intelligence. However, Dr. Gaur had a refreshing take on this.

“AI will not replace human intelligence; it will enhance it. It’s not artificial intelligence—it’s augmented intelligence. AI, when used correctly, can amplify human skills, improve precision, and drive innovation in healthcare.”

While AI is transforming personalized medicine, diagnostics, and treatment plans, he emphasized that the key is collaboration between AI and human expertise.

“If we don’t adopt AI, we will fall behind. The goal is not to fear AI but to use it to create what I call ‘awesome intelligence’—a fusion of human intuition and machine efficiency.”

Bringing AI to Government Healthcare: A Slow but Promising Journey

Unlike the private sector, where AI-driven technologies are quickly being implemented, government healthcare systems often face bureaucratic hurdles and slower regulatory processes.

Dr. Gaur, who has worked closely with both the private sector and government, explained the challenge:

“Technology evolves rapidly—think about how your smartphone gets updates every few weeks. But government regulations are reviewed every 3–5 years. By the time policies are updated, the technology they were meant for is already outdated.”

That said, he highlighted positive progress.

“The government is increasingly open to collaboration with private industries and researchers. The COVID-19 pandemic proved that when urgency is high, solutions can be found quickly. Now, we need to apply that same speed to AI and healthcare policies.”

India vs. Developed Countries: Where Can We Improve?

India has made significant strides in healthcare, but when compared to countries like the U.S., U.K., and Canada, there’s still a wide gap in accessibility.

“We have world-class hospitals in metro cities, but step outside the urban bubble—just 150 kilometers away—and the infrastructure starts to weaken. There’s a major imbalance in healthcare distribution.”

One of the biggest challenges is ensuring that quality healthcare reaches rural and remote areas.

“Health is a fundamental right. Someone in Delhi should have access to the same healthcare as someone in Mizoram or Ladakh. Right now, that’s not the case. But AI, telemedicine, and digital diagnostics can help bridge that gap.”

He believes that startups and disruptive innovations will play a crucial role in transforming India’s healthcare system.

“Yes, many healthcare startups fail, but failure leads to success. We need more startups, more ideas, and most importantly, faster adoption of these innovations by the government.”

A Message to Everyone: Make Health a Habit

Before concluding, Dr. Gaur left an important message for all listeners:

“Healthcare is not just the responsibility of doctors or policymakers. It’s a collective effort. Educate yourself, take care of your health, and build a culture where wellness is a habit, not just a vertical industry.“His words serve as a powerful reminder: healthcare isn’t just about medicine—it’s about community, awareness, and a shared commitment to well-being.

Composed By

InnoHEALTH magazine digital team

Listen to the full podcast on our YouTube channel: https://www.youtube.com/watch?v=4lLRLG9k3L0

The post Beyond Metro Cities: How AI Can Bring Healthcare to Rural India appeared first on InnoHEALTH magazine.

About the author

Anuj Jindal co-founded SureClaim to fix the broken claim experience of insurance customers. He believes technology can play a major role in empowering customers. His understanding is shaped by his decade long stint in healthcare and health-tech companies.

The post Are you filling the Health Insurance Claim? appeared first on InnoHEALTH magazine.